You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,233,171


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,233,171
Title:Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
Abstract: The present invention provides, inter alia, a compound having the structure: ##STR00001## Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
Inventor(s): Stockwell; Brent R. (New York, NY), Dixon; Scott J. (New York, NY), Skouta; Rachid (New York, NY)
Application Number:15/442,475
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 10,233,171

Introduction

Patents are a crucial component of innovation, providing exclusive rights to inventors and encouraging the development of new technologies. The United States Patent and Trademark Office (USPTO) plays a vital role in this process, evaluating patent applications to ensure they meet the criteria for patentability. This article will delve into the specifics of US Patent 10,233,171, analyzing its claims and the broader patent landscape, particularly in the context of recent USPTO guidance updates and judicial precedents.

Background on Patent Eligibility

To understand the patentability of any invention, it is essential to grasp the principles outlined in 35 U.S.C. § 101, which defines what subject matter is eligible for patenting. The Supreme Court has established that laws of nature, natural phenomena, and abstract ideas are not patentable, unless they are integrated into a practical application that provides a concrete technological improvement[3][2].

The Case of US Patent 10,233,171

While the specific details of US Patent 10,233,171 are not provided in the sources, we can apply general principles to analyze its potential patentability.

Claim Analysis

Patent claims must be carefully crafted to avoid being classified as abstract ideas or mere data processing steps. The 2024 USPTO guidance update emphasizes the importance of integrating judicial exceptions into practical applications. For instance, a claim that merely uses a mathematical model to manipulate data without applying it in a specific manner would likely be considered ineligible. However, if the claim specifies the use of the data in a real-world application, such as improving the accuracy of voice commands in a hands-free environment, it would be more likely to meet the criteria for patent eligibility[3].

Practical Application and Technological Improvement

The key to patent eligibility lies in demonstrating how the claimed method or system provides concrete benefits or solves specific problems in the relevant field. For example, if the patent claims involve using AI to enhance a particular technology, such as speech recognition, the claims must show how this application goes beyond mere data processing and provides a tangible outcome that directly benefits the technology[3].

Recent USPTO Guidance Update on AI Patents

The 2024 USPTO guidance update is particularly relevant for patents involving artificial intelligence (AI). This update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. The update provides examples of patent-eligible and ineligible claims, helping practitioners draft claims that avoid common section 101 rejections[3].

AI-Assisted Inventions

The guidance emphasizes that AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution. This means that claims must show how the AI is integrated into a practical application, rather than just being a tool for routine data processing[3].

Judicial Precedents and Patent Eligibility

Judicial decisions play a crucial role in shaping the patent landscape. The case of Electric Power Group, LLC v. Alstom S.A. illustrates how claims can be deemed ineligible if they fail to integrate abstract ideas into practical applications. In this case, the claims were directed to the abstract idea of monitoring and analyzing data from disparate sources without providing an inventive concept in the application of that abstract idea[2].

The Alice Framework

The Supreme Court's Alice Corp. v. CLS Bank Int’l decision established a two-stage framework for determining patent eligibility. First, it must be determined whether the claim is directed to a judicial exception (e.g., an abstract idea). If so, the second stage involves assessing whether the claim elements, both individually and as an ordered combination, add enough to transform the nature of the claim into a patent-eligible application. This framework is critical in evaluating the patentability of claims, especially in the context of AI and software-related inventions[2].

The Role of the USPTO in Patent Examination

The USPTO's internal databases and guidelines are essential in tracking and evaluating patent applications. For instance, the analysis of patent allowance rates, such as the first-action allowance rate, progenitor allowance rate, and family allowance rate, helps in understanding the complexity of the examination process. These metrics are crucial for applicants and practitioners to gauge the likelihood of their applications being allowed[1].

Artificial Intelligence Patent Dataset (AIPD)

The USPTO's Artificial Intelligence Patent Dataset (AIPD) is a valuable resource for researchers and policymakers. The AIPD 2023 update incorporates advanced machine learning techniques to identify AI-related patents, providing insights into the trends and impacts of AI inventions. This dataset can help in understanding the broader landscape of AI patents and how they are evaluated for patentability[4].

Key Takeaways

  • Practical Application: For a patent to be eligible, the claims must integrate judicial exceptions into practical applications that provide concrete technological improvements.
  • AI-Assisted Inventions: The use of AI in the development of an invention does not impact subject matter eligibility, provided there is significant human contribution.
  • Judicial Precedents: Judicial decisions, such as those under the Alice framework, are crucial in determining patent eligibility, especially for abstract ideas and software-related inventions.
  • USPTO Guidance: The 2024 USPTO guidance update provides clear examples and criteria for evaluating the patentability of AI-related inventions.
  • Data Analysis: The USPTO's internal databases and the AIPD are essential tools for understanding patent trends and the examination process.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The 2024 USPTO guidance update refines and clarifies the process for determining the patent eligibility of AI-related inventions, providing more tools for practitioners to evaluate and draft claims that are likely to avoid section 101 rejections.

How does the Alice framework impact patent eligibility?

The Alice framework involves a two-stage process to determine patent eligibility. First, it assesses whether the claim is directed to a judicial exception. If so, the second stage evaluates whether the claim elements transform the nature of the claim into a patent-eligible application.

What role does AI play in patent eligibility?

AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution. The focus remains on the claimed invention itself, ensuring AI-assisted inventions are evaluated on equal footing with other technologies.

How does the USPTO track and evaluate patent applications?

The USPTO uses internal databases to track and evaluate patent applications, analyzing metrics such as first-action allowance rates, progenitor allowance rates, and family allowance rates to understand the complexity of the examination process.

What is the Artificial Intelligence Patent Dataset (AIPD)?

The AIPD is a dataset created by the USPTO to identify and analyze AI-related patents. It incorporates advanced machine learning techniques and provides insights into the trends and impacts of AI inventions.

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. Retrieved from https://yjolt.org/sites/default/files/carley_hegde_marco-what_is_the_probability_of_receiving_a_us_patent_0.pdf
  2. United States Court of Appeals for the Federal Circuit. (2016). Electric Power Group, LLC v. Alstom S.A.. Retrieved from https://cafc.uscourts.gov/opinions-orders/15-1778.opinion.7-28-2016.1.pdf
  3. Mintz. (2024). Understanding the 2024 USPTO Guidance Update on AI Patent. Retrieved from https://www.mintz.com/insights-center/viewpoints/2231/2024-07-24-understanding-2024-uspto-guidance-update-ai-patent
  4. United States Patent and Trademark Office. (2023). Artificial Intelligence Patent Dataset (AIPD) 2023. Retrieved from https://www.uspto.gov/ip-policy/economic-research/research-datasets/artificial-intelligence-patent-dataset

More… ↓

⤷  Subscribe

Details for Patent 10,233,171

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 10,233,171 2032-04-02
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 10,233,171 2032-04-02
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 10,233,171 2032-04-02
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 10,233,171 2032-04-02
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 10,233,171 2032-04-02
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 March 05, 1973 10,233,171 2032-04-02
Genentech, Inc. ACTIVASE alteplase For Injection 103172 November 13, 1987 10,233,171 2032-04-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.